Vanguard Fiduciary Trust
KRYS icon

Vanguard Fiduciary Trust’s Krystal Biotech KRYS Stock Holding History

Vanguard Fiduciary Trust’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$70.4M Buy
189,528
+10,367
+6% +$3.1M 0.02% 682
2026
Q1 		$46.3M Buy
+179,161
New +$47.7M 0.01% 828

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Fiduciary Trust's KRYS Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Krystal Biotech (KRYS) stake by 5.8% in Q2 2026, buying an estimated $3.1M and bringing the position to 189,528 shares worth $70.4M. The position accounts for 0.02% of the portfolio, ranked #682.

Vanguard Fiduciary Trust first reported a position in KRYS in Q1 2026 and has held it in 2 quarters since. 419 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Vanguard Fiduciary Trust held 189,528 shares of Krystal Biotech worth $70.4M as of Q2 2026.
  • Vanguard Fiduciary Trust bought 10,367 Krystal Biotech shares in Q2 2026, an estimated $3.1M.
  • Krystal Biotech made up 0.02% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #682 holding.
  • Vanguard Fiduciary Trust first reported a position in Krystal Biotech in Q1 2026 and has held it in 2 quarters since.
  • 419 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.